Literature DB >> 2112120

Randomized trial comparing single dose versus fractionated irradiation for prevention of heterotopic bone: a preliminary report.

A Konski1, V Pellegrini, C Poulter, J DeVanny, R Rosier, C M Evarts, M Henzler, P Rubin.   

Abstract

Radiation therapy has been shown to prevent heterotopic bone formation in high risk patients undergoing total hip replacement. A number of doses have been used without a randomized trial comparing one dose regimen against another. A prospective randomized trial was undertaken comparing 10 Gy in 5 fractions versus 8 Gy in 1 fraction. Forty-seven patients have been randomized at the time of this evaluation with 37 patients eligible for analysis. The pre-operative, immediate post-operative and 2 month post-operative radiographs were graded. At the time of this analysis, 17 patients were randomized to the 8 Gy arm with 20 patients in the 10 Gy arm. Patients were treated with limited fields so as to only cover the area at risk for development of heterotopic bone to prevent adverse effects on biologic fixation of uncemented implants. When comparing the pre-operative, operative, and 2 month post-operative radiographs, only four patients (1 patient in the 8 Gy arm and 3 patients in the 10 Gy arm), had an increase in the score. No patient had an increase in score to a clinically significant level, usually grade 3 or 4. These preliminary results appear to show that 8 Gy in a single fraction can be as effective as 10 Gy in 5 fractions in preventing heterotopic bone in susceptible individuals. Further follow-up of the remaining patients may confirm this.

Entities:  

Mesh:

Year:  1990        PMID: 2112120     DOI: 10.1016/0360-3016(90)90450-x

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  8 in total

Review 1.  Heterotopic ossification: clinical and cellular aspects.

Authors:  J R Sawyer; M A Myers; R N Rosier; J E Puzas
Journal:  Calcif Tissue Int       Date:  1991-09       Impact factor: 4.333

2.  [Radiation therapy to prevent heterotopic ossification: example of a clinical trial].

Authors:  M H Seegenschmiedt
Journal:  Strahlenther Onkol       Date:  1997-12       Impact factor: 3.621

3.  [Prospective study on the prevention of heterotopic ossification after total hip replacement. Non-steroidal anti-inflammatory agents versus radiation therapy].

Authors:  O Kölbl; M Flentje; J Eulert; T Barthel; D Knelles; U Kraus
Journal:  Strahlenther Onkol       Date:  1997-12       Impact factor: 3.621

Review 4.  Prophylactic Radiotherapy of Hip Heterotopic Ossification: A Narrative Mini Review.

Authors:  Massimiliano De Paolis; Alessio Giuseppe Morganti; Erika Galietta; Luca Gaiani; Claudio Giannini; Andrea Sambri; Milly Buwenge; Gabriella Macchia; Francesco Deodato; Savino Cilla; Lidia Strigari; Michele Fiore; Silvia Cammelli
Journal:  In Vivo       Date:  2022 Mar-Apr       Impact factor: 2.155

Review 5.  [Research progress of traumatic heterotopic ossification].

Authors:  Guorui Cao; Fuxing Pei
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2022-03-15

6.  Prevention of heterotopic ossification in high-risk patients with total hip arthroplasty: the experience of a combined therapeutic protocol.

Authors:  Emilios E Pakos; Evita J Pitouli; Pericles G Tsekeris; Vasiliki Papathanasopoulou; Kosmas Stafilas; Theodore H Xenakis
Journal:  Int Orthop       Date:  2006-02-16       Impact factor: 3.075

7.  Perioperative high-dose-rate brachytherapy in the treatment of recurrent malignant gliomas.

Authors:  Maria Grazia Fabrini; Franco Perrone; Lucia De Franco; Francesco Pasqualetti; Silvia Grespi; Riccardo Vannozzi; Luca Cionini
Journal:  Strahlenther Onkol       Date:  2009-08-04       Impact factor: 3.621

Review 8.  Heterotopic Ossification: A Challenging Complication of Total Hip Arthroplasty: Risk Factors, Diagnosis, Prophylaxis, and Treatment.

Authors:  Paweł Łęgosz; Maciej Otworowski; Aleksandra Sibilska; Krzysztof Starszak; Daniel Kotrych; Adam Kwapisz; Marek Synder
Journal:  Biomed Res Int       Date:  2019-04-16       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.